A detailed history of Jpmorgan Chase & CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,048,856 shares of EXEL stock, worth $173 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,048,856
Previous 5,323,859 5.17%
Holding current value
$173 Million
Previous $126 Million 10.2%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$20.34 - $23.73 $5.59 Million - $6.53 Million
-275,003 Reduced 5.17%
5,048,856 $113 Million
Q1 2024

May 10, 2024

SELL
$20.17 - $23.93 $48.8 Million - $57.9 Million
-2,417,730 Reduced 31.23%
5,323,859 $126 Million
Q4 2023

Feb 12, 2024

BUY
$19.25 - $24.13 $1.8 Million - $2.25 Million
93,368 Added 1.22%
7,741,589 $186 Million
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $903,390 - $1.08 Million
-47,447 Reduced 0.62%
7,648,221 $167 Million
Q2 2023

Aug 11, 2023

SELL
$18.17 - $20.48 $1.25 Million - $1.41 Million
-68,779 Reduced 0.89%
7,695,668 $147 Million
Q1 2023

May 18, 2023

BUY
$16.3 - $19.41 $9.08 Million - $10.8 Million
557,058 Added 7.73%
7,764,447 $151 Million
Q1 2023

May 11, 2023

SELL
$16.3 - $19.41 $86.6 Million - $103 Million
-5,312,565 Reduced 42.43%
7,207,389 $140 Million
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $2.55 Million - $2.96 Million
170,325 Added 1.38%
12,519,954 $201 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $3.15 Million - $4.47 Million
200,726 Added 1.65%
12,349,629 $194 Million
Q2 2022

Aug 11, 2022

BUY
$17.44 - $23.16 $1.78 Million - $2.37 Million
102,300 Added 0.85%
12,148,903 $253 Million
Q1 2022

May 11, 2022

BUY
$17.03 - $22.67 $1.76 Million - $2.34 Million
103,192 Added 0.86%
12,046,603 $273 Million
Q4 2021

Feb 10, 2022

BUY
$15.84 - $21.88 $8.15 Million - $11.3 Million
514,336 Added 4.5%
11,943,411 $218 Million
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $186 Million - $242 Million
11,429,075 New
11,429,075 $242 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.